Kinpeygo® (targeted-release budesonide)

Kinpeygo® (targeted-release budesonide) - the first and only disease-modifying treatment approved across Europe and by NICE specifically for use in IgA nephropathy1,2

Kinpeygo® (targeted-release budesonide) is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/gram Prescribing Information can be found here

Find out more about Kinpeygo® (targeted release budesonide). Request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team

Man Looking Mobile

Lets stay connected!

Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?

References

1. European public assessment report (EPAR) Kinpeygo. EMA/570757/2022, last revised 05/2022. 2. Overview | Targeted-release budesonide for treating primary IgA nephropathy | Guidance | NICE. https://www.nice.org.uk/guidance/ta937 (Published: 20 December 2023).

Information

For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-122e | Date of Preparation: February 2024